TITLE

Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease: COMMENTARY

AUTHOR(S)
Rees, P. John
PUB. DATE
May 2004
SOURCE
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article covers a wide range of treatments for chronic obstructive pulmonary disease (COPD). Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been the absence of large, long-term studies, unlike the field of cardiology. In the controversial area of inhaled corticosteroid therapy for COPD, an attempt was made to rectify this paucity with several reasonably large studies that lasted 3 years. These studies provided some important answers, but still left unanswered questions Recent studies of COPD have concentrated on clinically relevant outcomes, such as exacerbations, quality of life, and admissions, although definitions of exacerbations vary. LA β[sub 2]As, tiotropium, and inhaled corticosteroids all reduce exacerbations by 20% to 30% relative to placebo.
ACCESSION #
13221819

 

Related Articles

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article focuses on the effects of commonly used treatments for chronic obstructive pulmonary disease on patient outcomes. In patients with chronic obstructive pulmonary disease, long-acting (LA) β[sub 2]-agonists and inhaled corticosteroids, with and without LA β[sub 2]As, reduce...

  • Twenty-four-hour duration of effect of intranasal corticosteroids for seasonal allergic rhinitis symptoms: Clinical evidence and relevance. DuBuske, Lawrence M. // American Journal of Rhinology & Allergy;Jul/Aug2012, Vol. 26 Issue 4, p287 

    Background: Seasonal allergic rhinitis (SAR) symptoms are often most severe and/or disruptive during overnight and morning hours, resulting in cognitive/performance impairments and reduced quality of life throughout the following day. Surveys of allergy patients and health care practitioners...

  • Systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Schweiger, Teresa A.; Zdanowicz, Martin // American Journal of Health-System Pharmacy;7/1/2010, Vol. 67 Issue 13, p1061 

    Purpose. The literature was reviewed to determine whether data support current treatment guideline recommendations regarding the use of systemic corticosteroids in the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. Summary. Exacerbations of COPD are common and can be...

  • Using exhaled NO concentrations to adjust inhaled corticosteroid dose maintained asthma control and reduced the dose. Smith, A. D.; Cowan, J. O.; Brassett, K. P.; Taylor, R. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p20 

    The article reports on a study to determine whether optimizing the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air can reduce asthma exacerbations and the daily dosage compared to the use of standard criteria for patients with chronic asthma. Patients aged 12-75...

  • Commentary. Rees, P. John // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p20 

    The article comments on a study by A. D. Smith and colleagues to determine whether optimizing the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air can reduce asthma exacerbations and the daily dosage compared to the use of standard criteria for patients with chronic...

  • Review: Inhaled corticosteroids slow the progression of airflow limitation in COPD.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p57 

    In patients with chronic obstructive pulmonary disease (COPD), inhaled corticosteroids reduce the progression of airflow limitation. Inhaled corticosteroids (ICS) slow the progression of airflow limitation in COPD Studies were selected if they were full reports of randomized controlled trials of...

  • Review: Inhaled corticosteroids slow the progression of airflow limitation in COPD: COMMENTARY. Greenstone, Michael // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p57 

    Chronic obstructive pulmonary disease (COPD) is largely a disease of vulnerable smokers in whom the normal age-related decline in lung function is accelerated from a mean of 30 mL/y to 60 mL/y. Unlike asthma, the airflow obstruction and airway inflammation of COPD respond poorly to...

  • Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology. Nadeem, Nighat J.; Taylor, Stephanie J. C.; Eldridge, Sandra M. // Respiratory Research;Aug2011, Vol. 12 Issue 8, p1 

    Inhaled corticosteroids (ICS) reduce COPD exacerbation frequency and slow decline in health related quality of life but have little effect on lung function, do not reduce mortality, and increase the risk of pneumonia. We systematically reviewed trials in which ICS have been withdrawn from...

  • Inhaled corticosteroids and COPD exacerbations. Kuritzky, Louis // Clinical Oncology Alert;Apr2010 Supplement 2, p8 

    The article discusses research on the effectiveness of inhaled corticosteroids (ICS) in preventing chronic obstructive pulmonary disease (COPD) exacerbation, by R. Agarwal and colleagues, published in the 2010 issue of "Chest."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics